What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
His primary areas of study are Internal medicine, Surgery, Gastroenterology, Crohn's disease and Ulcerative colitis.
As part of his studies on Internal medicine, Geert R. D'Haens frequently links adjacent subjects like Placebo.
His Surgery research is multidisciplinary, relying on both Adalimumab, Certolizumab pegol, Clinical trial and Dosing.
His Gastroenterology study combines topics from a wide range of disciplines, such as Crohn's Disease Activity Index, Intestinal mucosa, Rheumatoid arthritis and C-reactive protein.
His Crohn's disease study integrates concerns from other disciplines, such as Colonoscopy, Faecal calprotectin and Severity of illness.
His Ulcerative colitis study combines topics in areas such as Gastrointestinal agent, Interquartile range and Colitis.
His most cited work include:
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (2984 citations)
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial (971 citations)
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis (782 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease.
As a member of one scientific family, Geert R. D'Haens mostly works in the field of Internal medicine, focusing on Placebo and, on occasion, Maintenance therapy.
His study focuses on the intersection of Crohn's disease and fields such as Surgery with connections in the field of Azathioprine.
The various areas that Geert R. D'Haens examines in his Gastroenterology study include Moderate to severe, Adverse effect, Vedolizumab, Calprotectin and C-reactive protein.
His work deals with themes such as Prospective cohort study, Tofacitinib, Colitis and Quality of life, which intersect with Ulcerative colitis.
His studies link Intensive care medicine with Inflammatory bowel disease.
He most often published in these fields:
- Internal medicine (68.95%)
- Crohn's disease (47.37%)
- Gastroenterology (46.32%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (68.95%)
- Crohn's disease (47.37%)
- Gastroenterology (46.32%)
In recent papers he was focusing on the following fields of study:
Geert R. D'Haens mainly investigates Internal medicine, Crohn's disease, Gastroenterology, Ulcerative colitis and Inflammatory bowel disease.
Geert R. D'Haens performs multidisciplinary study in Internal medicine and In patient in his work.
His studies in Crohn's disease integrate themes in fields like Post-hoc analysis, Clinical trial, Surgery and Ustekinumab.
His research on Gastroenterology also deals with topics like
- Placebo which connect with Randomized controlled trial and Maintenance therapy,
- Receiver operating characteristic which is related to area like Area under the curve.
His Ulcerative colitis research is multidisciplinary, incorporating perspectives in Adverse effect, Prospective cohort study, Tofacitinib and Endoscopy.
His Inflammatory bowel disease research incorporates elements of Colorectal cancer, Colitis, Ultrasound and Intensive care medicine.
Between 2019 and 2021, his most popular works were:
- Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. (34 citations)
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. (34 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His primary scientific interests are in Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Placebo and, in certain cases, Endoscopy.
Geert R. D'Haens interconnects C-reactive protein, Phases of clinical research, Adverse effect, Maintenance therapy and Receiver operating characteristic in the investigation of issues within Gastroenterology.
Within one scientific family, Geert R. D'Haens focuses on topics pertaining to Hazard ratio under Crohn's disease, and may sometimes address concerns connected to Terminal Ileitis, Retrospective cohort study, Surgery, Proportional hazards model and Lower risk.
His Ulcerative colitis research includes themes of Interleukin 23, Cancer, Dysplasia and Adenoma.
His biological study spans a wide range of topics, including Interquartile range, Therapeutic drug monitoring, Drug, Intensive care medicine and Guselkumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
